Which adverse effect has been reported for evinacumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Evinacumab is a monoclonal antibody given by IV infusion, and its safety data show nasopharyngitis as a commonly reported adverse effect in clinical trials and labeling. This reflects the frequent upper respiratory tract symptoms seen with many biologics. Severe hypersensitivity reactions are possible with biologics but are uncommon for evinacumab. Injection-site irritation is unlikely since the drug is administered intravenously rather than subcutaneously. Fatigue can occur, but it is not as consistently reported as nasopharyngitis. Therefore, nasopharyngitis is the adverse effect most consistently associated with evinacumab in the data.